opioid receptor mu 1Genealiases: LMOR · M-OR-1 · MOP · MOR · MOR1 · OPRM
Q-omics provides the consensus-scored OPRM1 profile across patient tissues and cancer cell-line models. OPRM1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OPRM1 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, OPRM1 RNA expression shows 9,092 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where OPRM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OPRM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OPRM1 survival associations across molecular data types. OPRM1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OPRM1 RNA expression–survival associations across cancer types. High OPRM1 expression shows unfavorable associations in ACC, LIHC, KIRC, LUAD and UCS, but favorable associations in STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OPRM1 RNA expression.
This table summarizes OPRM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for OPRM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OPRM1 shows lower tumor expression in COAD, READ and THCA and higher tumor expression in HNSC, LUAD and LUSC. The HNSC box plot shows higher OPRM1 RNA expression in tumor versus normal tissue (log2 FC = +0.010, t-test p < 0.001).
This table shows molecular features associated with OPRM1 in patient tissues and cancer cell lines. In patient samples, OPRM1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, OPRM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LIVER.
